Position in NVS
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$963,984
-$368,912 QoQ
Shares Held
6,151
-29.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#633
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Sivia Capital Partners, LLC holds $16,248,994 across 14 Drug Manufacturers - General names. NVS ranks #5 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,555 | $4,263,974 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
47,373 | $2,729,632 | |
| 3 | MRK |
Merck & Co., Inc.
|
16,440 | $2,112,540 | |
| 4 | PFE |
Pfizer Inc
|
82,650 | $1,990,212 | |
| 5 | NVS |
Novartis AG
This page
|
6,151 | $963,984 | |
| 6 | JNJ |
Johnson & Johnson
|
3,459 | $878,482 | |
| 7 | BIIB |
Biogen Inc.
|
3,879 | $838,096 | |
| 8 | GSK |
GSK plc
|
10,340 | $542,022 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $963,984 | 6,151 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $1,332,896 | 8,726 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,874,342 | 13,595 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $951,540 | 7,420 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $963,118 | 7,959 | Shares | Sole | 2025-09-24 | |
| 2025-03-31 | $599,539 | 5,378 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $516,034 | 5,303 | Shares | Sole | 2025-01-13 | |
| 2024-09-30 | $679,078 | 5,904 | Shares | Sole | 2024-10-11 | |
| 2024-06-30 | $593,195 | 5,572 | Shares | Sole | 2024-08-05 | |
| 2024-03-31 | $517,021 | 5,345 | Shares | Sole | 2024-04-19 | |
| 2023-12-31 | $534,030 | 5,289 | Shares | Sole | 2024-03-13 | |
| No filing history on record for this holder in this stock. | ||||||